AxoGen (AXGN) Expected to Post Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.09 per share and revenue of $67.0990 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The firm had revenue of $61.46 million for the quarter, compared to analysts’ expectations of $57.85 million. On average, analysts expect AxoGen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Stock Performance

Shares of AXGN opened at $39.49 on Monday. AxoGen has a 52-week low of $12.39 and a 52-week high of $46.95. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. The firm’s fifty day moving average is $42.18 and its two-hundred day moving average is $37.09. The stock has a market cap of $2.10 billion, a PE ratio of -61.70 and a beta of 1.09.

Insiders Place Their Bets

In related news, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the sale, the director directly owned 11,050 shares in the company, valued at approximately $478,023. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy Mcbride Wendell sold 1,647 shares of AxoGen stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $42.60, for a total transaction of $70,162.20. Following the transaction, the director directly owned 93,826 shares in the company, valued at $3,996,987.60. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 29,041 shares of company stock valued at $1,268,792 in the last three months. 2.44% of the stock is currently owned by insiders.

Institutional Trading of AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in AxoGen by 86.1% in the fourth quarter. Invesco Ltd. now owns 189,345 shares of the medical equipment provider’s stock valued at $6,197,000 after acquiring an additional 87,622 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in AxoGen by 41.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 15,857 shares of the medical equipment provider’s stock worth $503,000 after acquiring an additional 4,664 shares during the last quarter. XTX Topco Ltd acquired a new stake in AxoGen during the fourth quarter worth $228,000. Uniplan Investment Counsel Inc. raised its position in AxoGen by 7.5% in the fourth quarter. Uniplan Investment Counsel Inc. now owns 170,620 shares of the medical equipment provider’s stock valued at $5,584,000 after purchasing an additional 11,882 shares during the period. Finally, Susquehanna Portfolio Strategies LLC raised its position in AxoGen by 22.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 114,724 shares of the medical equipment provider’s stock valued at $3,755,000 after purchasing an additional 21,356 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. Wells Fargo & Company boosted their price target on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Citizens Jmp raised their target price on shares of AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AxoGen currently has a consensus rating of “Moderate Buy” and an average price target of $46.50.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.